Bluebird bio announced the official opening of its first wholly owned manufacturing facility in Durham, N.C., that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the […]
A new study in the UK has shown that EZH2, an epigenetic protein, can potentially be a new therapeutic target for the treatment of acute myeloid leukemia (AML). A group of researchers at the Cambridge […]
SMi Group is excited to share 5 spotlight session being covered at this year’s West Coast Pharmaceutical Microbiology by Roche, Genentech, Xellia Pharmaceuticals, Bristol-Myers Squibb and Celgene Corporation, sessions will cover contamination control & microbial […]
In just 3 weeks, the highly anticipated Pharmaceutical Microbiology East Coast conference and exhibition will take place inBoston, USA,on April 10 and 11, 2019. SMi Group are delighted to share 10 key reasons to why […]
Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy […]